Glycosylated Ferritin in Macrophagic Activation Syndromes

NCT02143986 | Recruiting

• 1 other identifier: CHUB-FERRITGLY01
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

In healthy subjects, from 50 to 80 % of the serum ferritin is glycosylated \[1, 2\] . A decrease in the percentage of ferritin glycosylation can be observed in inflammatory diseases, malignancies, infections, or liver disease but is rarely less than 20% \[3 , 4\] . Percentage of glycosylated ferritin below 20% have been described in patients with adult Still's disease and haemophagocytosis lymphohistiocytic syndromes (HLH). The glycosylated ferritin has been included in the diagnostic criteria for Still's disease in adults. A cut-off of less than 20 % has a sensitivity and specificity of 72 and 69 % respectively , and 35 and 94 % when combined with a total ferritin level greater than 5 times normal value. This parameter was also suggested to be a more specific marker to confirm a diagnosis of HLH than a high ferritin level ( \> 500μg / L). However, several limitations of this parameter were highlighted, some conditions making its interpretation difficult : particularly in cases of major hepatic cytolysis and severe sepsis (miliary tuberculosis, lymphoma and disease Adult Still). It is not always possible to distinguish severe sepsis, HLH syndrome and Still's disease. A fine analysis of various glycoforms components of ferritin could be used to distinguish different subgroups of patients. Few data are available on the mechanism of secretion and glycosylation of ferritin, but the investigators assume that the glycosylation patterns of ferritin may vary between different disease states and reflect distinct underlying pathophysiological mechanisms.

Conditions

Still's Disease, Adult-Onset; Sepsis; Macrophagic Activation Syndrome

Keywords

sepsis; Macrophagic activation syndrome; Ferritin; Still's disease

Outcome Measures

Primary Outcomes (1)

• Fraction of glycosylated ferritin in serum

  One year

Study Arms (4)

Macrophagic activation syndrome

Still's disease

Hyperferritinemia

Sepsis

Eligibility Criteria

• Age: Up to 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All consecutive patients admitted in our hospital with inclusion criteria with a suspicion of sepsis or macrophagic activation syndrome.

You may qualify if:

• Suspicion of sepsis, macrophagic activation syndrome, Still's disease or hyperferritinemia (malignant disease, hepatic cytolysis)

You may not qualify if:

• Normal ferritin level

Sponsors & Collaborators

• Brugmann University Hospital: lead
• Université Libre de Bruxelles: collaborator

Study Sites (1)

Brugmann University Hospital

Brussels, 1020, Belgium

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum

MeSH Terms

Conditions

Still's Disease, Adult-Onset; Sepsis; Arthritis, Juvenile

Condition Hierarchy (Ancestors)

Arthritis, Rheumatoid; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Francis Corazza, MD, PhD

CONTACT

32-2-4772506; francis.corazza@ulb.ac.be

France Debaugnies, Pharm

CONTACT

32-2-4772507; france.debaugnies@chu-brugmann.be

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of laboratory of immunology

Study Record Dates

• First Submitted: May 19, 2014
• First Posted: May 21, 2014
• Study Start: May 1, 2014
• Primary Completion (Estimated): December 1, 2030
• Study Completion (Estimated): December 1, 2030
• Last Updated: October 6, 2025

Record last verified: 2025-10

Locations

BE (1)